Lee MJ, Lin JC, Qureshi R, Greenberg PB. Predictors of citation count for systematic reviews in ophthalmology. Graefes Arch Clin Exp Ophthalmol. 2023 Jan;261(1):281-282. PubMed PMID: 35943581
Qureshi R, Mayo-Wilson E, Li T. Harms in Systematic Reviews Paper 1: An introduction to research on harms. J Clin Epidemiol. 2022 Mar;143:186-196. PubMed PMID: 34742788
Qureshi R, Mayo-Wilson E, Rittiphairoj T, McAdams-DeMarco M, Guallar E, Li T. Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin. J Clin Epidemiol. 2022 Mar;143:212-223. PubMed PMID: 34742789
Qureshi R, Mayo-Wilson E, Rittiphairoj T, McAdams-DeMarco M, Guallar E, Li T. Harms in Systematic Reviews Paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms. J Clin Epidemiol. 2022 Mar;143:224-241. PubMed PMID: 34742790
Phillips R, Cro S, Wheeler G, Bond S, Morris TP, Creanor S, Hewitt C, Love S, Lopes A, Schlackow I, Gamble C, MacLennan G, Habron C, Gordon AC, Vergis N, Li T, Qureshi R, Everett CC, Holmes J, Kirkham A, Peckitt C, Pirrie S, Ahmed N, Collett L, Cornelius V. Visualising harms in publications of randomised controlled trials: consensus and recommendations. BMJ. 2022 May 16;377:e068983. PubMed PMID: 35577357
Qureshi R, Gough A, Loudon K. The SPIRIT Checklist-lessons from the experience of SPIRIT protocol editors. Trials. 2022 Apr 27;23(1):359. PubMed PMID: 35477436
Protasio JN, King A, Pasquale LR, Barton K, Bonnar J, Qureshi R, Virgili G, Azuara-Blanco A. How Can We Quantify and Compare Harm in Surgical Trials?. Am J Ophthalmol. 2022 Sep;241:64-70. PubMed PMID: 35526589
McCann P, Kruoch Z, Qureshi R, Li T. Effectiveness of interventions for dry eye: a protocol for an overview of systematic reviews. BMJ Open. 2022 Jun 7;12(6):e058708. PubMed PMID: 35672062
Qureshi R, Chen X, Goerg C, Mayo-Wilson E, Dickinson S, Golzarri-Arroyo L, Hong H, Phillips R, Cornelius V, McAdams DeMarco M, Guallar E, Li T. Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials. Epidemiol Rev. 2022 Dec 21;44(1):55-66. PubMed PMID: 36065832
McCann P, Abraham AG, Mukhopadhyay A, Panagiotopoulou K, Chen H, Rittiphairoj T, Gregory DG, Hauswirth SG, Ifantides C, Qureshi R, Liu SH, Saldanha IJ, Li T. Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2022 Dec 1;140(12):1181-1192. PubMed PMID: 36301551
Kang C, Lin JC, Qureshi R, Scherer R, Greenberg PB. Author, study, and publication metrics of brief reports and full-length research articles in ophthalmology journals. Clin Exp Ophthalmol. 2022 Dec 23. [Epub ahead of print] PubMed PMID: 36562707
Monaco W, Qureshi R, Meng H, Arif A, Aggarwal S. Risk factors for vision loss among nursing home residents: A cross-sectional analysis. Investigative Ophthalmology and Visual Science. 2022; 63(7):4238
Qureshi R, E JY, Han G, Rittiphairoj T, Ng S, Wilson R, Abariga S, Li T. Certainty of evidence in Cochrane Eyes and Vision systematic reviews. Investigative Ophthalmology and Visual Science. 2022; 63(7):2137
Qureshi R, Phillips R, Cornelius V, Mayo-Wilson E, Goerg C, Li T. Data visualization approaches to presenting harms in clinical trials. Clinical Trials. 2022; 64-65 [CP I 5-4]